Previous close | 15.55 |
Open | 15.55 |
Bid | 16.40 |
Ask | 16.80 |
Strike | 26.00 |
Expiry date | 2024-08-16 |
Day's range | 15.55 - 15.55 |
Contract range | N/A |
Volume | |
Open interest | 31 |
DraftKings (DKNG) posted first-quarter earnings results, showing revenue increased over 50% year-over-year. According to the report, part of their success is due in part to stronger-than-expected customer acquisition and retention. DraftKings CEO Jason Robins joins Catalysts to give insight into the sports betting platform's performance and how legislation is forming around gambling from state to state. Robins weighs in on how the company will push for sports betting legislation this year: "I definitely think we'll get a few bills done this year, but I don't know that we'll get quite as many as we did last year... I think right now, a lot of states, because of the election year, sometimes that slows things down a little bit on the legislation front. That said, we're right now in the heart of legislative season. A lot of states are still in session. It's super hard to predict. We'll see. Hopefully, we'll get a few over the line this year." For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Nicholas Jacobino
Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen ‘very encouraged’ by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year.